ATL 201

Drug Profile

ATL 201

Alternative Names: Astatine-211-J591; Astatine-211-labelled-anti-PSMA monoclonal antibody J591

Latest Information Update: 08 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ATLAB Pharma
  • Developer Telix Pharmaceuticals
  • Class Drug conjugates; Immunotoxins; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 18 Jan 2017 Atlab Pharma and Telix Pharmaceuticals plan a phase IIb trial for in Prostate cancer (Metastatic disease)
  • 18 Jan 2017 Preclinical trials in Prostate cancer in France (Parenteral) before January 2017
  • 18 Jan 2017 Telix Pharmaceuticals and Atlab Pharma agree to co-develop ATL 201 for Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top